About Phi Therapeutics
Phi Therapeutics is a private company based in Petaluma, California. It has reported $8,890,830 raised in three offerings on Form D since June 2019. Its chief executive is Neil Giugno.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | Apr 6, 2023amended Jun 26, 2024 | $7,655,830fully sold | 22 | $347K | Equity, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 22, 2021 | Jan 6, 2022 | $660,000of $2.0M target | 7 | $94,286 | DebtRule 506(b) | Form D ↗ |
| May 24, 2019 | Jun 4, 2019 | $575,000of $1.5M target | 4 | $143K | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $8,890,830 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Phi Therapeutics's Form D filed Jun 26, 2024.
JL
Jun Li
Director
YV
Yug Varma
Executive officer and director
NG
Neil Giugno
Chief Executive Officer and director
KL
Kevin Law
Director
Earlier filings also listed Maria Cho (director and promoter, last listed Jan 2022).